Return on Capital (ROC)
Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
Abbott Laboratories, ROIC calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 5,601) | 5,289) | 6,718) | 7,014) | 4,838) | |
| Invested capital2 | 60,065) | 59,651) | 61,288) | 62,076) | 60,387) | |
| Performance Ratio | ||||||
| ROIC3 | 9.32% | 8.87% | 10.96% | 11.30% | 8.01% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| Cigna Group | 5.96% | 5.63% | 8.53% | 6.88% | 9.84% | |
| CVS Health Corp. | 4.04% | 7.07% | 3.13% | 7.01% | 6.63% | |
| Elevance Health Inc. | 8.97% | 9.21% | 10.24% | 11.26% | 8.37% | |
| Intuitive Surgical Inc. | 28.75% | 22.30% | 22.01% | 37.63% | 25.62% | |
| Medtronic PLC | 5.44% | 5.89% | 7.02% | 5.59% | 6.20% | |
| UnitedHealth Group Inc. | 9.54% | 14.59% | 13.68% | 13.51% | 13.84% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2024 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 5,601 ÷ 60,065 = 9.32%
4 Click competitor name to see calculations.
| Performance ratio | Description | The company |
|---|---|---|
| ROIC | A measure of the periodic, after tax, cash-on-cash yield earned in the business. | Abbott Laboratories ROIC deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Decomposition of ROIC
Abbott Laboratories, decomposition of ROIC
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The primary reason for the increase in return on invested capital (ROIC) over 2024 year is the increase in efficiency measured by turnover of capital (TO) ratio.
Operating Profit Margin (OPM)
Abbott Laboratories, OPM calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 5,601) | 5,289) | 6,718) | 7,014) | 4,838) | |
| Add: Cash operating taxes2 | 1,626) | 1,463) | 2,118) | 1,759) | 718) | |
| Net operating profit before taxes (NOPBT) | 7,226) | 6,753) | 8,836) | 8,772) | 5,556) | |
| Net sales | 41,950) | 40,109) | 43,653) | 43,075) | 34,608) | |
| Profitability Ratio | ||||||
| OPM3 | 17.23% | 16.84% | 20.24% | 20.37% | 16.05% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| Cigna Group | 2.75% | 3.57% | 5.39% | 4.69% | 7.72% | |
| CVS Health Corp. | 2.10% | 3.78% | 2.45% | 4.32% | 4.79% | |
| Elevance Health Inc. | 5.46% | 5.32% | 5.64% | 6.58% | 5.88% | |
| Intuitive Surgical Inc. | 32.39% | 28.14% | 26.19% | 33.56% | 28.14% | |
| Medtronic PLC | 17.14% | 19.63% | 19.15% | 16.48% | 17.88% | |
| UnitedHealth Group Inc. | 6.31% | 9.14% | 9.13% | 8.33% | 9.15% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2024 Calculation
OPM = 100 × NOPBT ÷ Net sales
= 100 × 7,226 ÷ 41,950 = 17.23%
4 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| OPM | The operating profit margin (OPM) is the ratio of pretax economic earnings, or NOPBT, to sales. | Abbott Laboratories OPM deteriorated from 2022 to 2023 but then slightly improved from 2023 to 2024. |
Turnover of Capital (TO)
Abbott Laboratories, TO calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net sales | 41,950) | 40,109) | 43,653) | 43,075) | 34,608) | |
| Invested capital1 | 60,065) | 59,651) | 61,288) | 62,076) | 60,387) | |
| Efficiency Ratio | ||||||
| TO2 | 0.70 | 0.67 | 0.71 | 0.69 | 0.57 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| Cigna Group | 3.02 | 2.26 | 2.09 | 1.90 | 1.70 | |
| CVS Health Corp. | 2.82 | 2.65 | 2.60 | 2.22 | 1.96 | |
| Elevance Health Inc. | 2.24 | 2.44 | 2.33 | 2.14 | 2.13 | |
| Intuitive Surgical Inc. | 1.07 | 1.00 | 1.16 | 1.27 | 0.98 | |
| Medtronic PLC | 0.47 | 0.44 | 0.46 | 0.42 | 0.41 | |
| UnitedHealth Group Inc. | 1.99 | 2.01 | 1.95 | 2.04 | 1.96 | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 Invested capital. See details »
2 2024 Calculation
TO = Net sales ÷ Invested capital
= 41,950 ÷ 60,065 = 0.70
3 Click competitor name to see calculations.
| Efficiency ratio | Description | The company |
|---|---|---|
| TO | The turnover of capital (TO) is the ratio of sales to invested capital. Capital turnover is a function of the efficiency of working capital management and of net fixed assets. | Abbott Laboratories TO deteriorated from 2022 to 2023 but then improved from 2023 to 2024 not reaching 2022 level. |
Effective Cash Tax Rate (CTR)
Abbott Laboratories, CTR calculation, comparison to benchmarks
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 5,601) | 5,289) | 6,718) | 7,014) | 4,838) | |
| Add: Cash operating taxes2 | 1,626) | 1,463) | 2,118) | 1,759) | 718) | |
| Net operating profit before taxes (NOPBT) | 7,226) | 6,753) | 8,836) | 8,772) | 5,556) | |
| Tax Rate | ||||||
| CTR3 | 22.50% | 21.67% | 23.97% | 20.05% | 12.92% | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| Cigna Group | 28.08% | 30.27% | 24.44% | 23.01% | 24.93% | |
| CVS Health Corp. | 31.66% | 29.40% | 50.90% | 27.09% | 29.36% | |
| Elevance Health Inc. | 26.66% | 29.13% | 22.01% | 20.22% | 33.27% | |
| Intuitive Surgical Inc. | 17.42% | 20.94% | 27.40% | 11.76% | 6.67% | |
| Medtronic PLC | 32.75% | 32.28% | 19.53% | 18.59% | 14.72% | |
| UnitedHealth Group Inc. | 24.04% | 20.64% | 23.25% | 20.32% | 22.88% | |
Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2024 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 1,626 ÷ 7,226 = 22.50%
4 Click competitor name to see calculations.
| Tax rate | Description | The company |
|---|---|---|
| CTR | Effective cash tax rate on operating income. | Abbott Laboratories CTR decreased from 2022 to 2023 but then slightly increased from 2023 to 2024. |